GLP-1s May Cut Risk of 10 Obesity-Related Cancers in Diabetes Patients: Study

1. Study Findings: GLP-1 medications, such as Wegovy and Ozempic, may lower the risk of developing 10 out of 13 obesity-related cancers in patients with type 2 diabetes compared to insulin therapy.
2. Cancer Types: The study found significant risk reductions for cancers including bladder, meningioma, pancreatic, liver, esophageal, colorectal, endometrial, ovarian, kidney, and multiple myeloma.
3. Risk Reduction: The risk of certain cancers, such as gallbladder, pancreatic, and liver cancer, was reduced by more than 50%.
4. Limitations: The study did not find a reduced risk of postmenopausal breast cancer, stomach cancer, or thyroid cancer, and there were limitations in the study design and data accuracy.
5. Future Research: Experts emphasize the need for further studies to confirm the findings and explore potential side effects, as well as to investigate the role of GLP-1 drugs in preventing specific types of cancer.